The Year in Review 2025
For over 30 years, we’ve been helping you bring better drugs to the people who need them, faster—and 2025 was no different. Here’s a look at some of the year’s highlights!
We proudly celebrated 30 years as a drug development solution company. From our early days specializing in generic drug testing and bioanalysis to becoming a full-service, integrated early-phase CRO and CDMO with nine sites across North America, this anniversary video from CEO Chris Perkin highlights how far we’ve come.
Visitors toaltasciences.com
Hours ofvideos watched
EmailsRead
This video series hit the scene in 2025, and stars Altasciences and Standard CRO (aka Stan) as they find themselves in situations that highlight the standard drug development approach versus our own—often leading to embarrassing moments for Stan.
Hosted by Lisa Sanford, Vice President, Commercial Strategy and Engagement Launched in 2025, the podcast follows host Lisa Sanford and industry experts in candid conversations about drug development, sharing insider perspectives on challenges in the industry, emerging trends and hot topics, and so much more.
This popular series returned in 2025 with even more stories that take you behind the science. These real accounts from Altascientists show the immeasurable impact drug development has on everyday life.
Attended
Altascientists and seasoned industry consultants took to our blog to reflect on conferences, case studies, and the drug development landscape. Here’s a selection of standout pieces from throughout the year that you'll want to explore.
The future of drug development looks better and brighter than ever. Take a look at some of the ways we pushed the limits to bring life-saving drugs to those who need them—and our collaborations with partners who share our commitment to making a difference.
- Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences
- Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™
- Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts
- Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development
- Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category
published
- Designing IND-Enabling Toxicity Studies for Complex Drug Modalities: Going Beyond the Classical Approach
- Critical Imaging Risks in GLP-1 and Neurology Studies: What You Need to Know
- Juvenile Nonhuman Primate Toxicology Studies
- Nonhuman Primate PK/PD Studies With Fast Start-Ups and Seamless Transitions
- Standardization and Harmonization of Altasciences Historical Control Database Development Using Certara SEND Explorer® for Integrated Toxicological Evaluation
- Pushing the Envelope: Detection of Generic Human IgG in Cynomolgus Monkey Serum via Quantitative ELISA
- Navigating the Uncharted Territory of Assessing Psychedelics in Human Abuse Potential Studies
- Spray Drying Nanosuspensions: A Novel Approach for Improved Bioavailability in Solid Dosage Forms
- Clinical Trials Without Boundaries: Multi-Site Solutions at Altasciences
- ClinDMO: Where Clinical Innovation Meets Manufacturing Excellence
- CNS Drug Development Solutions, Simplified
- ISSUE NO. 43 — Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics
- ISSUE NO. 44 — The Importance of Cytokine Release Assays to Derisk the Development of Immunomodulatory Drugs
- ISSUE NO. 45 — Discovery Studies: An Agile Approach to Early Data for Quicker Decisions
- ISSUE NO. 46 — Spray-Dried Dispersions: An Innovative Solution for Poorly Soluble Molecules in Early-Phase Drug Development
- ISSUE NO. 47 — Size Matters: The Sinclair Nanopig® as a Translational Non-Rodent Model in Preclinical Research
- 30 Years of Innovation in Drug Development: The Evolution of the Contract Research Organization
- Best Practices for Preclinical Dose Range Finding Studies
- Responsible AI Frees Scientists to Focus on Science By Nicole Maciolek for STAT News
- In Vivo Characterization of ONL1204, a Small Peptide Inhibitor of the Fas Receptor, as a Potential Neuroprotective Therapy for Geographic Atrophy and Dry Age-Related Macular Degeneration
- The Golden Era of GLP-1 Drugs: How Will it Impact Medicine and Society? By Dr. Gaetano Morelli, MD, for Biopharma Dive
As we put a bow on 2025 and look ahead, we want to take a moment to thank each of you for choosing Altasciences to bring your molecules from lead candidate selection to clinical proof of concept—and beyond.
Our vision for 2026 is clear: We remain dedicated to making your programs shine, providing the data and guidance you can trust to realize your goals and dreams.
Kick off 2026 with the latest Choose Altasciences video:
